Athenex, Inc.(NASDAQ : ATNX)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||-1.60%||162.58||0.7%||$1033.26m|
|MRK||Merck & Co., Inc.||-0.67%||76.71||0.7%||$980.93m|
|LLY||Eli Lilly & Co.||-1.09%||219.80||1.1%||$902.43m|
|BMY||Bristol-Myers Squibb Co.||-0.63%||66.35||1.0%||$618.54m|
|ANVS||Annovis Bio, Inc.||4.64%||94.23||0.0%||$320.63m|
|BTX||Brooklyn ImmunoTherapeutics, Inc.||10.20%||16.91||12.4%||$104.70m|
|CNST||Constellation Pharmaceuticals, Inc.||-0.18%||33.76||0.0%||$104.65m|
Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer. It operates through the following segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Global Supply Chain Platform segment provides supply of active pharmaceutical ingredients (APIs) for clinical and commercial efforts. The Commercial Platform segment involves the sale and marketing of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.